Annovis Bio Announces 2026 Annual Meeting Results and Election of Directors

Annovis Bio, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026. During the meeting, stockholders voted on and approved five key proposals. First, five nominees—Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White—were elected to the Board of Directors to serve one-year terms. Second, the appointment of Ernst & Young LLP as the company's independent auditors was ratified. Third, stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the total shares issuable from 4,000,000 to 5,500,000 and raising the annual award limit from 400,000 to 600,000 shares. Fourth, the compensation of named executive officers was approved on an advisory basis. Finally, stockholders selected a biennial (every two years) frequency for future advisory votes on executive compensation. Approximately 62.65% of the company's outstanding common stock was represented at the meeting. Annovis Bio confirmed it will follow the two-year frequency for compensation votes moving forward.